Improving CAR-T cell therapy for kidney cancer
Advancing Next Generation CAR-T cells for Renal Cell Carcinoma
This study is looking at ways to make CAR-T cell therapy better for people with kidney cancer by using new technology to improve how these immune cells fight tumors, which could lead to more effective treatment options for patients.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cellinfinity Bio, INC. NIH-funded |
| Lab location | 1 site (Milford, United States) |
| Project ID | NIH-11007712 on NIH RePORTER |
What this research studies
This research focuses on enhancing CAR-T cell therapy specifically for patients with Renal Cell Carcinoma (RCC), a common type of kidney cancer. The team is utilizing advanced CRISPR technology to identify genetic modifications that can improve the effectiveness of CAR-T cells against solid tumors. By modifying T cells to enhance their immune response and persistence, the goal is to overcome current limitations of CAR-T therapy in treating RCC. Patients may benefit from a more effective treatment option that could lead to better outcomes in managing their cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with Renal Cell Carcinoma who have not responded well to existing treatments.
Not a fit: Patients with non-cancerous kidney conditions or those who do not have Renal Cell Carcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective CAR-T cell therapy option for patients with Renal Cell Carcinoma.
How similar studies have performed: Previous research has shown promising results in enhancing CAR-T cell therapy for hematological malignancies, but this approach for solid tumors like RCC is still being explored.
Where this research is happening
Milford, United States
- Cellinfinity Bio, INC. — Milford, United States (Active)
Researchers
- Principal investigator: Patel, Premal — Cellinfinity Bio, INC.
- Study coordinator: Patel, Premal
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.